Subscribe To
GRCL / Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
GRCL News
By GlobeNewsWire
November 1, 2023
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDA more_horizontal
By GlobeNewsWire
September 14, 2023
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a gl more_horizontal
By GlobeNewsWire
August 24, 2023
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal
By Seeking Alpha
August 14, 2023
Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants William Cao - Chairman, C more_horizontal
By The Motley Fool
August 7, 2023
Why Shares of Gracell Biotechnologies Are Rising Monday
Gracell Biotechnologies is a clinical-stage biotech company based in China. The company's lead therapy is in four different trials to treat various di more_horizontal
By GlobeNewsWire
July 31, 2023
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a glob more_horizontal
By Zacks Investment Research
June 14, 2023
Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
Shares of Gracell (GRCL) increase after it reported positive data from two clinical studies, which evaluated its experimental CAR T cell therapy drug more_horizontal
By The Motley Fool
June 13, 2023
Why Shares of Gracell Biotechnologies Jumped Tuesday
Two analysts upgraded their ratings for Gracell Biotechnologies' stock. Over the weekend, Gracell announced positive follow-up trial data regarding it more_horizontal